https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-07-09 / Vaccine 2008 Aug;26(36):4716-24
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-07-09 / Vaccine 2008 Aug;26(36):4716-242008-07-09 00:00:002023-03-07 13:11:25Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-07-01 / J. Immunol. 2008 Jul;181(1):808-21
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-07-01 / J. Immunol. 2008 Jul;181(1):808-212008-07-01 00:00:002008-07-01 00:00:00Fusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T cells while concomitant exposure to IL-12, CpG oligodeoxynucleotides, and anti-CD3/CD28 promotes the expansion of activated tumor reactive cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-06-27 / BMC Immunol. 2008 Jun;9:32
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-06-27 / BMC Immunol. 2008 Jun;9:322008-06-27 00:00:002019-02-15 08:50:17Ex vivo recovery and activation of dysfunctional, anergic, monocyte-derived dendritic cells from patients with operable breast cancer: critical role of IFN-alpha
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-05-15 / Cancer Res. 2008 May;68(10):3854-62
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-05-15 / Cancer Res. 2008 May;68(10):3854-622008-05-15 00:00:002008-05-15 00:00:00Cancer immunotherapy using in vitro genetically modified targeted dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-04-01 / Immunol. Rev. 2008 Apr;222:256-76
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-04-01 / Immunol. Rev. 2008 Apr;222:256-762008-04-01 00:00:002008-04-01 00:00:00Reengineering dendritic cell-based anti-cancer vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-03-01 / Int J Hyperthermia 2008 Mar;24(2):171-81
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-03-01 / Int J Hyperthermia 2008 Mar;24(2):171-812008-03-01 00:00:002008-03-01 00:00:00The importance of schedule in whole body thermochemotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-02-05 / Br. J. Cancer 2008 Feb;98(4):784-91
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-02-05 / Br. J. Cancer 2008 Feb;98(4):784-912008-02-05 00:00:002008-02-05 00:00:00Immunisation with ’naïve‘ syngeneic dendritic cells protects mice from tumour challenge
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-02-01 / Zhonghua Zhong Liu Za Zhi 2008 Feb;30(2):107-11
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-02-01 / Zhonghua Zhong Liu Za Zhi 2008 Feb;30(2):107-112008-02-01 00:00:002008-02-01 00:00:00[Dendritic cells elicit cellular immune response by targeting to capture breast cancer cells]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-12-01 / Int. J. Oncol. 2007 Dec;31(6):1357-65
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-12-01 / Int. J. Oncol. 2007 Dec;31(6):1357-652007-12-01 00:00:002007-12-01 00:00:00Characteristics of hybrid cells obtained by dendritic cell/tumour cell fusion in a T-47D breast cancer cell line model indicate their potential as anti-tumour vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-10-15 / Cancer 2007 Oct;110(8):1677-86
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-10-15 / Cancer 2007 Oct;110(8):1677-862007-10-15 00:00:002007-10-15 00:00:00Breast cancer vaccines: promise for the future or pipe dream?
